Masimo Announces UniView

April 2, 2018

UniView Aggregates and Displays Patient Data From Multiple Devices to Minimize Clinician Cognitive Overload and Maximize Patient Safety

IRVINE, Calif.--(BUSINESS WIRE)--Apr. 2, 2018-- Masimo (NASDAQ: MASI) announced today the release of UniView™, an integrated display of real-time data and alarms from multiple Masimo and third-party devices, designed to reduce clinician cognitive overload and improve patient safety. UniView promotes data sharing and team coordination among multiple clinicians.

This press release features multimedia. View the full release here:

Masimo UniView™ (Photo: Business Wire)

Masimo UniView™ (Photo: Business Wire)

In operating rooms (ORs), in intensive care units (ICUs), and in other areas which involve multiple clinical disciplines, clinicians are often unable to simultaneously view data from all of the various medical devices in use, resulting in information that remains siloed among, for example, anesthesiologists, surgeons, and nurses. In addition, the plethora of displays and user interfaces adds to cognitive overload that can cause clinician burnout and suboptimal patient care.

UniView solves these problems by bringing together data from a variety of sources – such as patient monitors, ventilators, anesthesia gas machines, and IV pumps – and providing a supplementary display for them, clearly organized, on one or more large, central monitors, so that all clinicians can simultaneously view and act upon the same, comprehensive real-time patient status and historical trends. Visual alarm indicators, relayed from the connected devices, help clinicians recognize patient distress and target areas for immediate focus. UniView is suitable for any area where comprehensive, logically organized, and timely data are key to supporting good clinical care.

UniView also provides tailored, use-case-specific screen layouts which optimize the presentation of advanced and integrated parameters, trend data, and waveforms for a variety of clinical scenarios, making it a versatile solution in many environments. For example:

  • In Overview layout, view monitoring data from all connected point-of-care and therapeutic devices including waveforms and alarms, for an overview of patient status.
  • In Hemodynamics layout, view trend data for noninvasive hemoglobin (SpHb®), pleth variability index (PVi®), and pulse rate to aid in visualizing patient status over time.
  • In Oxygenation layout, view ventilator waveforms alongside noninvasive trended hemoglobin (SpHb) and oxygen saturation (SpO2) to monitor a patient’s oxygenation status.
  • In Sedation layout, view high-fidelity EEG waveforms, patient state index (PSi), and anesthesia machine data to monitor a patient’s sedation.

In addition, hospitals will be able customize the view as preferred and even take advantage of individual customization using Masimo MyView™ technology.

Joe Kiani, Founder and CEO of Masimo, said, “We are answering clinicians’ calls for logical, clinically transformational cockpits for the collaborative ORs and ICUs of the future. UniView is a great example of Masimo’s ongoing commitment to automating patient care, whether it’s making pulse oximeters accurate when you need that accuracy most, creating new noninvasive monitoring technologies such as SpHb, or in this case, unsiloing data, enhancing connectivity, and communicating patient data as effectively and efficiently as possible, so that clinicians can focus more on their patients. We look forward to introducing additional enhancements soon – helping to bring automation and connectivity to the next level.”

UniView builds on the success of Kite™, which projects data from Root® on a larger screen, by aggregating data from all of the connected devices in a room, including third-party ones, so that a supplemental display of all monitoring data can be viewed by all. UniView works in conjunction with Masimo Iris Gateway™ and Patient SafetyNet™* connectivity platforms. Complementing UniView, the recently announced Masimo Replica™ allows clinicians to view similar monitoring data for multiple patients, as well as view and respond to alarms and alerts, all from a smart phone, regardless of location.

@MasimoInnovates | #Masimo

*The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,1 improve CCHD screening in newborns,2 and, when used for continuous monitoring with Masimo Patient SafetyNet™* in post-surgical wards, reduce rapid response activations and costs.3,4,5 Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,6 and is the primary pulse oximetry at 17 of the top 20 hospitals listed in the 2017-18 U.S. News and World Report Best Hospitals Honor Roll.7 In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), and more recently, Oxygen Reserve Index (ORi™), in addition to SpO2, pulse rate, and perfusion index (Pi). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect® (MOC-9®) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7® wearable patient monitor, iSpO2® pulse oximeter for smartphones, and the MightySat™ fingertip pulse oximeter. Additional information about Masimo and its products may be found at Published clinical studies on Masimo products can be found at

ORi has not received FDA 510(k) clearance and is not available for sale in the United States.

*The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.


  1. Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
  2. de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
  3. Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.
  4. Taenzer AH et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
  5. McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
  6. Estimate: Masimo data on file.

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo UniView™, Iris Gateway™, and Patient SafetyNet™. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo UniView, Iris Gateway, and Patient SafetyNet, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Source: Masimo

Evan Lamb, 949-396-3376